BETHESDA, Md.--(BUSINESS WIRE)--Micromet, Inc. (NASDAQ:MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that data on two of its BiTE antibody development programs will be reported at the 52nd Annual American Society of Hematology Annual Meeting, to be held December 4 – 7 in Orlando, Florida.
